Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 10Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 273Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 181Neoplasms 174Lung Neoplasms 137Multiple Myeloma 136Neoplasm Metastasis 101Colorectal Neoplasms 100Melanoma 87Ovarian Neoplasms 80Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 73Lymphoma 69Carcinoma, Renal Cell 65Leukemia, Lymphocytic, Chronic, B-Cell 64Brain Neoplasms 63Lymphoma, Non-Hodgkin 62Squamous Cell Carcinoma of Head and Neck 61Recurrence 56Urinary Bladder Neoplasms 55Hematologic Neoplasms 55Carcinoma, Hepatocellular 54Head and Neck Neoplasms 53Triple Negative Breast Neoplasms 51Lymphoma, Follicular 48Glioblastoma 48Endometrial Neoplasms 47Uterine Cervical Neoplasms 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Sarcoma 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Autoimmune Diseases × 90 days × Clear all
NCT06359041 2026-05-18

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Cabaletta Bio

Phase 1/2 Active not recruiting
12 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡